TY - JOUR
T1 - The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome
T2 - Therapeutic response
AU - Azziz, R.
N1 - Funding Information:
Received July 8, 1993; revised and accepted October 29, 1993. * Presented in part at The American Fertility Society, Washington, D.C., October 13 to 18, 1990, and at The American Fertility Society, New Orleans, Louisiana, October 21 to November 5, 1992. t Supported in part by grant R01-HD29364-01A1 from the National Institutes of Health, Bethesda, Maryland. :\: Reprint requests: Ricardo Azziz, M.D., The University of Alabama at Birmingham, Department of Obstetrics and Gynecology, 618 South 20th Street, ORB 549, Birmingham, Alabama 35233-7333.
PY - 1994
Y1 - 1994
N2 - The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome affects between 2% and 5% of hirsute women and is characterized by INS resistance, elevated INS levels, acanthosis nigricans, and androgen excess. These patients' response to therapy is unclear, although long-acting GnRH-a suppression has been proposed. The objective of this study was to determine the success of OC in suppressing the hyperandrogenemia of five patients with the hyperandrogenic-insulin-resistant acanthosis nigricans syndrome and the subsequent response to GnRH-a suppression of those women failing initial therapy. After 6 months of OC and SPA therapy, four patients experienced adequate suppression of free T. an increase in SHBG levels, and a subjective improvement in hair growth rate. Two also reported an improvement in hair texture. The total and free T levels in the fifth patient did not suppress after 8 months of OC therapy. Nevertheless, in this patient the administration of a GnRH-a along with hormonal replacement and SPA adequately suppressed free and total T, increased SHBG, and dramatically decreased the shaving interval. In conclusion, although GnRH-a suppression and hormonal replacement can be helpful in patients not responding to standard therapy, the majority of patients with the hyperandrogenic-insulin-resistant acanthosis nigricans syndrome will respond favorably to OC treatment. It is also clear that although hyperinsulinemia augments LH-stimulated androgen biosynthesis in vivo, it does not appear to be able to initiate or maintain androgen production in the absence of adequate gonadotropin stimulation.
AB - The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome affects between 2% and 5% of hirsute women and is characterized by INS resistance, elevated INS levels, acanthosis nigricans, and androgen excess. These patients' response to therapy is unclear, although long-acting GnRH-a suppression has been proposed. The objective of this study was to determine the success of OC in suppressing the hyperandrogenemia of five patients with the hyperandrogenic-insulin-resistant acanthosis nigricans syndrome and the subsequent response to GnRH-a suppression of those women failing initial therapy. After 6 months of OC and SPA therapy, four patients experienced adequate suppression of free T. an increase in SHBG levels, and a subjective improvement in hair growth rate. Two also reported an improvement in hair texture. The total and free T levels in the fifth patient did not suppress after 8 months of OC therapy. Nevertheless, in this patient the administration of a GnRH-a along with hormonal replacement and SPA adequately suppressed free and total T, increased SHBG, and dramatically decreased the shaving interval. In conclusion, although GnRH-a suppression and hormonal replacement can be helpful in patients not responding to standard therapy, the majority of patients with the hyperandrogenic-insulin-resistant acanthosis nigricans syndrome will respond favorably to OC treatment. It is also clear that although hyperinsulinemia augments LH-stimulated androgen biosynthesis in vivo, it does not appear to be able to initiate or maintain androgen production in the absence of adequate gonadotropin stimulation.
KW - Insulin resistance
KW - acanthosis nigricans
KW - androgen excess
KW - hirsutism
KW - leuprolide acetate
UR - http://www.scopus.com/inward/record.url?scp=0028206948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028206948&partnerID=8YFLogxK
U2 - 10.1016/s0015-0282(16)56599-6
DO - 10.1016/s0015-0282(16)56599-6
M3 - Article
C2 - 8137990
AN - SCOPUS:0028206948
SN - 0015-0282
VL - 61
SP - 570
EP - 572
JO - Fertility and Sterility
JF - Fertility and Sterility
IS - 3
ER -